News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,836 Results
Type
Article (14278)
Company Profile (281)
Press Release (254277)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79568)
Career Advice (153)
Deals (13232)
Drug Delivery (35)
Drug Development (50484)
Employer Resources (31)
FDA (5730)
Job Trends (5140)
News (144503)
Policy (10038)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21688)
ALS (68)
Alzheimer's disease (849)
Antibody-drug conjugate (ADC) (108)
Approvals (5755)
Artificial intelligence (132)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (160)
Cancer (1514)
Cardiovascular disease (120)
Career advice (134)
Career pathing (2)
CAR-T (121)
Cell therapy (337)
Cervical cancer (9)
Clinical research (41170)
Collaboration (557)
Compensation (275)
Complete response letters (13)
COVID-19 (1034)
CRISPR (44)
C-suite (171)
Cystic fibrosis (77)
Data (1592)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1303)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (91)
Earnings (30063)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48774)
Executive appointments (471)
FDA (6494)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (509)
Gene editing (102)
Generative AI (10)
Gene therapy (260)
GLP-1 (370)
Government (1084)
Grass and pollen (2)
Guidances (66)
Healthcare (6598)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (96)
Indications (20)
Infectious disease (1100)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7280)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (214)
Leadership (3)
Legal (1387)
Liver cancer (34)
Lung cancer (207)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (147)
MASH (59)
Medical device (2603)
Medtech (2604)
Mergers & acquisitions (6290)
Metabolic disorders (402)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (71)
Neuropsychiatric disorders (25)
Neuroscience (1268)
NextGen: Class of 2025 (2019)
Non-profit (852)
Now hiring (22)
Obesity (197)
Opinion (102)
Ovarian cancer (66)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (121)
Partnered (8)
Patents (135)
Patient recruitment (82)
Peanut (35)
People (25692)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14537)
Phase II (19153)
Phase III (12105)
Pipeline (915)
Policy (48)
Postmarket research (856)
Preclinical (6154)
Press Release (30)
Prostate cancer (63)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (296)
Real estate (1420)
Recruiting (12)
Regulatory (8679)
Reports (16)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (62)
Series A (99)
Series B (66)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1976)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (216)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (110)
Last 7 days (552)
Last 30 days (1771)
Last 365 days (19387)
2025 (6903)
2024 (20568)
2023 (22418)
2022 (26824)
2021 (27812)
2020 (23362)
2019 (16234)
2018 (11743)
2017 (13753)
2016 (11848)
2015 (14351)
2014 (10395)
2013 (7485)
2012 (7533)
2011 (7617)
2010 (7431)
Location
Africa (148)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17347)
Australia (2942)
California (4039)
Canada (1169)
China (373)
Colorado (152)
Connecticut (154)
Delaware (109)
Europe (37341)
Florida (491)
Georgia (121)
Idaho (16)
Illinois (238)
India (10)
Indiana (94)
Iowa (2)
Japan (78)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (492)
Massachusetts (3207)
Michigan (72)
Minnesota (150)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (999)
New Mexico (12)
New York (1079)
North Carolina (567)
North Dakota (5)
Northern California (1800)
Ohio (114)
Oklahoma (9)
Oregon (21)
Pennsylvania (760)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1552)
Tennessee (25)
Texas (468)
United States (13775)
Utah (56)
Virginia (83)
Washington D.C. (31)
Washington State (358)
Wisconsin (16)
268,836 Results for "ifm therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Novartis Buys IFM Due in Potential $835M Deal, Gains Access to Antagonist Program
IFM Therapeutics announced Wednesday its subsidiary IFM Due has been acquired by Novartis. The acquisition provides the Swiss pharma with full rights to IFM Due’s portfolio of STING antagonists targeting inflammation-driven diseases.
March 13, 2024
·
1 min read
·
Tyler Patchen
Deals
Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System
IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, announced today that Novartis has exercised its option to acquire all of the outstanding capital stock of IFM Due, a subsidiary company of IFM.
March 13, 2024
·
3 min read
Business
IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due
IFM Therapeutics (IFM), today announced that IFM Due, an IFM subsidiary company, has extended its collaboration and exclusive option agreement with Novartis to develop immunotherapies that inhibit the cGAS-STING pathway to treat a range of serious inflammatory and autoimmune diseases.
December 1, 2021
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Press Releases
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
May 8, 2025
·
6 min read
Deals
IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre
IFM Therapeutics announced the completion of the previously-announced acquisition of its subsidiary, IFM Tre, by Novartis.
May 8, 2019
·
1 min read
Press Releases
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
April 17, 2025
·
13 min read
Press Releases
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
April 15, 2025
·
7 min read
Press Releases
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
May 8, 2025
·
1 min read
1 of 26,884
Next
